Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Stein

Showing results (81-90 of 143) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|September 4, 2015
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancerAlexander Stein, Djordje Atanackovic, Bert Hildebrandt, et al.
Oncology Research and Treatment|February 14, 2017
Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal CancerJulia Quidde, Laura Denne, Andreas Kutscheidt, et al.
Future Oncology (London, England)|May 17, 2021
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancerMarkus Moehler, Maurice Michel, Alexander Stein, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II studyAlexander Stein, Dirk Arnold, Peter C Thuss-Patience, et al.
BMC Cancer|October 15, 2014
Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study resultsRalf Hofheinz, Volker Petersen, Manfred Kindler, et al.
BMC Cancer|August 18, 2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literatureAlexander Stein, Gabriel Glockzin, Andreas Wienke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2020
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerChiara Cremolini, Carlotta Antoniotti, Alexander Stein, et al.
Nature|July 7, 2017
Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3Stefan Schoebel, Wei Mi, Alexander Stein, et al.
Frontiers in Oncology|February 11, 2020
Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK SignalingJoseph Tintelnot, Sina Metz, Marie Trentmann, et al.
International Journal of Cancer|July 17, 2023
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapyThorsten Oliver Goetze, Alexander Stein, Sylvie Lorenzen, et al.
Pageof 15

Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|September 4, 2015
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancerAlexander Stein, Djordje Atanackovic, Bert Hildebrandt, et al.
Oncology Research and Treatment|February 14, 2017
Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal CancerJulia Quidde, Laura Denne, Andreas Kutscheidt, et al.
Future Oncology (London, England)|May 17, 2021
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancerMarkus Moehler, Maurice Michel, Alexander Stein, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II studyAlexander Stein, Dirk Arnold, Peter C Thuss-Patience, et al.
BMC Cancer|October 15, 2014
Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study resultsRalf Hofheinz, Volker Petersen, Manfred Kindler, et al.
BMC Cancer|August 18, 2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literatureAlexander Stein, Gabriel Glockzin, Andreas Wienke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2020
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerChiara Cremolini, Carlotta Antoniotti, Alexander Stein, et al.
Nature|July 7, 2017
Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3Stefan Schoebel, Wei Mi, Alexander Stein, et al.
Frontiers in Oncology|February 11, 2020
Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK SignalingJoseph Tintelnot, Sina Metz, Marie Trentmann, et al.
International Journal of Cancer|July 17, 2023
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapyThorsten Oliver Goetze, Alexander Stein, Sylvie Lorenzen, et al.
Pageof 15